Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Phase 3

Completed

Conditions: Congenital Hemophilia A

Interventions: Biological: rVIII-SingleChain

First Posted Date: 2014-03-21

Last Posted Date: 2017-01-27

Lead Sponsor: CSL Behring

Target Recruit Count: 84

Registration Number: NCT02093897

Locations: 🇺🇦
Study Site, Lviv, Ukraine

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Biological: rIX-FP

First Posted Date: 2014-02-04

Last Posted Date: 2022-07-14

Lead Sponsor: CSL Behring

Target Recruit Count: 97

Registration Number: NCT02053792

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Indiana Hemophilia & Thrombosis Center Inc., Indianapolis, Indiana, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 39 locations

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 3

Completed

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions: Biological: IgPro20

First Posted Date: 2014-01-06

Last Posted Date: 2018-10-02

Lead Sponsor: CSL Behring

Target Recruit Count: 82

Registration Number: NCT02027701

Locations: 🇺🇸
Site Reference 8400181, Birmingham, Alabama, United States
🇺🇸
Site Reference 8400167, Los Angeles, California, United States
🇺🇸
Site Reference 8400166, Kansas City, Kansas, United States

and more 30 locations

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Clazakizumab
Drug: Placebo (Matching with Clazakizumab)

First Posted Date: 2013-12-19

Last Posted Date: 2021-05-12

Lead Sponsor: CSL Behring

Target Recruit Count: 143

Registration Number: NCT02015520

Locations: 🇺🇸
Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States
🇺🇸
Mercy Clinic Hot Springs Communities, Hot Springs, Arkansas, United States
🇺🇸
Valerius Med Group & Res Ctr Of Greater Long Beach, Inc., Long Beach, California, United States

and more 22 locations

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: Higher-volume C1-esterase inhibitor
Biological: Low-volume C1-esterase inhibitor
Biological: Higher-volume placebo
Biological: Low-volume placebo

First Posted Date: 2013-07-31

Last Posted Date: 2021-01-29

Lead Sponsor: CSL Behring

Target Recruit Count: 90

Registration Number: NCT01912456

Locations: 🇬🇧
Study Site, London, United Kingdom

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Phase 1

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: Berinert
Biological: CSL830

First Posted Date: 2013-01-04

Last Posted Date: 2013-04-05

Lead Sponsor: CSL Behring

Target Recruit Count: 16

Registration Number: NCT01760343

Locations: 🇩🇪
Study Site, Berlin, Germany

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Biological: rIX-FP

First Posted Date: 2012-08-10

Last Posted Date: 2016-05-09

Lead Sponsor: CSL Behring

Target Recruit Count: 27

Registration Number: NCT01662531

Locations: 🇦🇺
The Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia
🇦🇺
The Children's Hospital at Westmead, Westmead, Australia
🇦🇹
AKH Wien (Paediatrics), Wien, Austria

and more 14 locations

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Phase 1

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: C1-esterase inhibitor - single intravenous dose
Biological: C1-esterase inhibitor - subcutaneous medium dose
Biological: C1-esterase inhibitor - subcutaneous low dose
Biological: C1-esterase inhibitor - subcutaneous high dose

First Posted Date: 2012-04-12

Last Posted Date: 2021-02-01

Lead Sponsor: CSL Behring

Target Recruit Count: 18

Registration Number: NCT01576523

Locations: 🇩🇪
Study Site, Mainz, Germany

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Biological: Placebo matching with BMS-945429
Biological: BMS-945429

First Posted Date: 2012-03-06

Last Posted Date: 2021-12-03

Lead Sponsor: CSL Behring

Target Recruit Count: 72

Registration Number: NCT01545050

Locations: 🇺🇸
University Of California, San Diego, La Jolla, California, United States
🇺🇸
Precision Research Institute, Llc, San Diego, California, United States
🇺🇸
South Denver Gastroenterology, Pc, Lone Tree, Colorado, United States

and more 6 locations

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Phase 3

Completed

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Polyradiculoneuropathy

Interventions: Biological: IgPro10
Biological: IgPro20 (low dose)
Biological: Placebo
Biological: IgPro20 (high dose)

First Posted Date: 2012-03-06

Last Posted Date: 2018-07-05

Lead Sponsor: CSL Behring

Target Recruit Count: 208

Registration Number: NCT01545076

Locations: 🇺🇸
Site reference 8400181, Birmingham, Alabama, United States
🇺🇸
Site reference 8400173, Phoenix, Arizona, United States
🇺🇸
Site reference 8400172, Phoenix, Arizona, United States

and more 88 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy